Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bellerophon Ther Com (BLPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Bellerophon Appoints Ted Wang, Ph.D., of Puissance Capital Management, to its Board of Directors

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the appointment of Ted Wang, Ph.D., Chief Investment Officer of Puissance Capital Management, to...

BLPH : 2.62 (+8.26%)
Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the third quarter ended September 30, 2017.

BLPH : 2.62 (+8.26%)
Bellerophon Announces $23 Million Private Placement

Financing will support the continued development of the company's INOpulse platform with Phase 3 clinical trials in Pulmonary Arterial Hypertension and Phase 2 trials in Pulmonary Hypertension associated...

BLPH : 2.62 (+8.26%)
Bellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will provide a corporate overview at...

BLPH : 2.62 (+8.26%)
Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse(R) for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced positive top line data from a Phase 2 clinical trial evaluating INOpulse(R) in patients with Pulmonary...

BLPH : 2.62 (+8.26%)
Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse(R) in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced agreement with the U.S. Food and Drug Administration (FDA) on the Phase 2 study design for INOpulse(R)...

BLPH : 2.62 (+8.26%)
Biotech Stock Performance Review -- Alder Biopharma, Ardelyx, Bellerophon Therapeutics, and Corbus Pharma

If you want a Stock Review on ALDR, ARDX, BLPH or CRBP then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Today's research on DailyStockTracker.com...

CRBP : 7.15 (-2.05%)
ALDR : 10.75 (+0.47%)
ARDX : 5.90 (+0.85%)
BLPH : 2.62 (+8.26%)
Positive Clinical Data on INOpulse(R) Presented at the American Thoracic Society 113th International Conference

Acute and Chronic Benefits Demonstrated with INOpulse in Patients with PH-IPF; Patients Achieved Statistically Significant Increases in Blood Vessel Volume; Consistent Improvements were Observed in Hemodynamics,...

BLPH : 2.62 (+8.26%)
The Difference Between Spectacular News and No News

NEW YORK, NY / ACCESSWIRE / March 21, 2017 / Biotech firms are speculative in many ways, especially when investing in lower priced stocks. FDA trials can take a nose dive, resulting in the stock price...

ESPR : 58.38 (+1.07%)
BLPH : 2.62 (+8.26%)
Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the fourth quarter and full year ended December...

BLPH : 2.62 (+8.26%)
Biotech and Pharma Stocks Rise on Optimism in the Markets Fueling Acquisitions and new Product Launches

PALM BEACH, Florida, March 7, 2017 /PRNewswire/ --

TGTX : 8.25 (unch)
IPXL : 18.65 (+4.78%)
XTNT : 0.57 (unch)
BLPH : 2.62 (+8.26%)
Biotech and Pharma Stocks Rise on Optimism in the Markets Fueling Acquisitions and new Product Launches

PALM BEACH, Florida , March 7, 2017 /PRNewswire/ --

TGTX : 8.25 (unch)
KAST : 0.0700 (-12.50%)
IPXL : 18.65 (+4.78%)
XTNT : 0.57 (unch)
BLPH : 2.62 (+8.26%)
4 Best Performing ETFs & Stocks of Last Week

Utilities, gold, high-dividend stocks, and other safe haven avenues led the way higher last week.

XLU : 55.02 (-0.56%)
INAP : 15.67 (+0.97%)
RORE : 15.84 (+0.60%)
DOD : 22.67 (-2.91%)
VXZ : 18.27 (-1.56%)
LMIA : 13.99 (-0.43%)
BLPH : 2.62 (+8.26%)
SPWR : 9.37 (+4.23%)
4 Best Performing ETFs & Stocks of Last Week

Utilities, gold, high-dividend stocks, and other safe haven avenues led the way higher last week.

XLU : 55.02 (-0.56%)
INAP : 15.67 (+0.97%)
RORE : 15.84 (+0.60%)
DOD : 22.67 (-2.91%)
VXZ : 18.27 (-1.56%)
LMIA : 13.99 (-0.43%)
BLPH : 2.62 (+8.26%)
SPWR : 9.37 (+4.23%)
LifeSci Capital Initiates Coverage of Bellerophon Therapeutics

Developing a Treatment for Select Cardiopulmonary Diseases using INOpulse, a Portable Drug/Device Combination Delivering Pulse Nitric Oxide; Report Available here: http://www.lifescicapital.com/equity-research/bellerophon/...

BLPH : 2.62 (+8.26%)

Van Meerten Stock Picks

5 Great Mid Caps
  Today you will find that I have varied a little bit from my usual search criteria.
KBH +0.30 , IPGP +2.52 , FSLR +1.07 , NVR -6.91 , TTWO +2.17
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.22%) this morning are up +0.16% and European stocks are down -0.34% at a 1-week low. Investors continue to pour money into U.S. equity funds at the expense of European stock funds.... Read More

Chart of the Day

Chart of the Day

Maximus (MMS) is the Barchart CHartr of the Day.  The governmental consulting firm has a Trend Spotter buy signal, a Weighted Alpha of 32.85+ and gained 31.28% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed the Friday session with most contracts as much as a penny lower. A private export sale of 134,503 MT of corn was sold to Costa Rica as announced by the USDA through their daily export reporting system. The Friday Commitment of Tra...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.